CervoMed (NASDAQ:CRVO) Given Buy Rating at D. Boral Capital

CervoMed (NASDAQ:CRVO)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $10.00 target price on the stock. D. Boral Capital’s target price points to a potential upside of 12.99% from the company’s current price.

A number of other research analysts have also recently commented on the stock. Chardan Capital raised shares of CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Thursday, March 13th. Roth Capital upgraded shares of CervoMed to a “strong-buy” rating in a report on Thursday, December 5th. Canaccord Genuity Group lifted their target price on shares of CervoMed from $12.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, March 18th. Brookline Capital Management upgraded CervoMed from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. Finally, Jones Trading upgraded CervoMed from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Thursday, March 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $27.50.

CervoMed Stock Performance

CRVO stock opened at $8.85 on Wednesday. CervoMed has a one year low of $1.80 and a one year high of $25.92. The firm has a market cap of $77.02 million, a PE ratio of -4.36 and a beta of 1.84. The firm’s 50 day moving average price is $3.61 and its 200-day moving average price is $7.68.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Monday, March 17th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The business had revenue of $2.16 million during the quarter, compared to analysts’ expectations of $1.51 million. Equities research analysts predict that CervoMed will post -1.88 EPS for the current fiscal year.

Institutional Trading of CervoMed

Large investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in CervoMed in the fourth quarter valued at $26,000. DRW Securities LLC acquired a new stake in CervoMed in the 4th quarter valued at about $30,000. Mariner LLC purchased a new position in shares of CervoMed in the 4th quarter valued at about $30,000. BNP Paribas Financial Markets acquired a new position in shares of CervoMed during the fourth quarter worth about $32,000. Finally, JPMorgan Chase & Co. increased its stake in shares of CervoMed by 251.8% during the fourth quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock worth $34,000 after buying an additional 10,352 shares during the period. Hedge funds and other institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.